Copyright Reports & Markets. All rights reserved.

Global Irritable Bowel Syndrome (IBS) Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Irritable Bowel Syndrome (IBS) Market Overview

      • 1.1 Product Overview and Scope of Irritable Bowel Syndrome (IBS)
      • 1.2 Irritable Bowel Syndrome (IBS) Segment by Type
        • 1.2.1 Global Irritable Bowel Syndrome (IBS) Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 IBS-D Drug
        • 1.2.3 IBS-C Drug
        • 1.2.4 Other
      • 1.3 Irritable Bowel Syndrome (IBS) Segment by Application
        • 1.3.1 Irritable Bowel Syndrome (IBS) Consumption Comparison by Application (2014-2025)
        • 1.3.2 Women
        • 1.3.3 Men
      • 1.3 Global Irritable Bowel Syndrome (IBS) Market by Region
        • 1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Irritable Bowel Syndrome (IBS) Market Size
        • 1.4.1 Global Irritable Bowel Syndrome (IBS) Revenue (2014-2025)
        • 1.4.2 Global Irritable Bowel Syndrome (IBS) Production (2014-2025)

      2 Global Irritable Bowel Syndrome (IBS) Market Competition by Manufacturers

      • 2.1 Global Irritable Bowel Syndrome (IBS) Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Irritable Bowel Syndrome (IBS) Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Irritable Bowel Syndrome (IBS) Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Irritable Bowel Syndrome (IBS) Production Sites, Area Served, Product Types
      • 2.5 Irritable Bowel Syndrome (IBS) Market Competitive Situation and Trends
        • 2.5.1 Irritable Bowel Syndrome (IBS) Market Concentration Rate
        • 2.5.2 Irritable Bowel Syndrome (IBS) Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Irritable Bowel Syndrome (IBS) Production Market Share by Regions

      • 3.1 Global Irritable Bowel Syndrome (IBS) Production Market Share by Regions
      • 3.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Irritable Bowel Syndrome (IBS) Production
        • 3.4.1 North America Irritable Bowel Syndrome (IBS) Production Growth Rate (2014-2019)
        • 3.4.2 North America Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Irritable Bowel Syndrome (IBS) Production
        • 3.5.1 Europe Irritable Bowel Syndrome (IBS) Production Growth Rate (2014-2019)
        • 3.5.2 Europe Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Irritable Bowel Syndrome (IBS) Production (2014-2019)
        • 3.6.1 China Irritable Bowel Syndrome (IBS) Production Growth Rate (2014-2019)
        • 3.6.2 China Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Irritable Bowel Syndrome (IBS) Production (2014-2019)
        • 3.7.1 Japan Irritable Bowel Syndrome (IBS) Production Growth Rate (2014-2019)
        • 3.7.2 Japan Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Irritable Bowel Syndrome (IBS) Consumption by Regions

      • 4.1 Global Irritable Bowel Syndrome (IBS) Consumption by Regions
      • 4.2 North America Irritable Bowel Syndrome (IBS) Consumption (2014-2019)
      • 4.3 Europe Irritable Bowel Syndrome (IBS) Consumption (2014-2019)
      • 4.4 China Irritable Bowel Syndrome (IBS) Consumption (2014-2019)
      • 4.5 Japan Irritable Bowel Syndrome (IBS) Consumption (2014-2019)

      5 Global Irritable Bowel Syndrome (IBS) Production, Revenue, Price Trend by Type

      • 5.1 Global Irritable Bowel Syndrome (IBS) Production Market Share by Type (2014-2019)
      • 5.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2014-2019)
      • 5.3 Global Irritable Bowel Syndrome (IBS) Price by Type (2014-2019)
      • 5.4 Global Irritable Bowel Syndrome (IBS) Production Growth by Type (2014-2019)

      6 Global Irritable Bowel Syndrome (IBS) Market Analysis by Applications

      • 6.1 Global Irritable Bowel Syndrome (IBS) Consumption Market Share by Application (2014-2019)
      • 6.2 Global Irritable Bowel Syndrome (IBS) Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Irritable Bowel Syndrome (IBS) Business

      • 7.1 Allergan
        • 7.1.1 Allergan Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.1.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.1.3 Allergan Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Valeant Pharmaceuticals
        • 7.2.1 Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.2.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.2.3 Valeant Pharmaceuticals Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Takeda
        • 7.3.1 Takeda Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.3.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.3.3 Takeda Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Sucampo Pharmaceuticals
        • 7.4.1 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.4.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.4.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 McNeil Consumer Healthcare
        • 7.5.1 McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.5.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.5.3 McNeil Consumer Healthcare Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Sebela Pharmaceuticals
        • 7.6.1 Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.6.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.6.3 Sebela Pharmaceuticals Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Astellas Pharmaceuticals
        • 7.7.1 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.7.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.7.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 IM HealthScience
        • 7.8.1 IM HealthScience Irritable Bowel Syndrome (IBS) Production Sites and Area Served
        • 7.8.2 Irritable Bowel Syndrome (IBS) Product Introduction, Application and Specification
        • 7.8.3 IM HealthScience Irritable Bowel Syndrome (IBS) Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served

      8 Irritable Bowel Syndrome (IBS) Manufacturing Cost Analysis

      • 8.1 Irritable Bowel Syndrome (IBS) Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Irritable Bowel Syndrome (IBS)
      • 8.4 Irritable Bowel Syndrome (IBS) Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Irritable Bowel Syndrome (IBS) Distributors List
      • 9.3 Irritable Bowel Syndrome (IBS) Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Irritable Bowel Syndrome (IBS) Market Forecast

      • 11.1 Global Irritable Bowel Syndrome (IBS) Production, Revenue Forecast
        • 11.1.1 Global Irritable Bowel Syndrome (IBS) Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Irritable Bowel Syndrome (IBS) Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Irritable Bowel Syndrome (IBS) Price and Trend Forecast (2019-2025)
      • 11.2 Global Irritable Bowel Syndrome (IBS) Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Irritable Bowel Syndrome (IBS) Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Irritable Bowel Syndrome (IBS) Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Irritable Bowel Syndrome (IBS) Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Irritable Bowel Syndrome (IBS) Production, Revenue Forecast (2019-2025)
      • 11.3 Global Irritable Bowel Syndrome (IBS) Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Irritable Bowel Syndrome (IBS) Consumption Forecast (2019-2025)
        • 11.3.2 Europe Irritable Bowel Syndrome (IBS) Consumption Forecast (2019-2025)
        • 11.3.3 China Irritable Bowel Syndrome (IBS) Consumption Forecast (2019-2025)
        • 11.3.4 Japan Irritable Bowel Syndrome (IBS) Consumption Forecast (2019-2025)
      • 11.4 Global Irritable Bowel Syndrome (IBS) Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Irritable Bowel Syndrome (IBS) Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
        Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.
        The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.

        The global Irritable Bowel Syndrome (IBS) market is valued at 2640 million US$ in 2018 is expected to reach 8650 million US$ by the end of 2025, growing at a CAGR of 16.0% during 2019-2025.
        This report focuses on Irritable Bowel Syndrome (IBS) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome (IBS) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Allergan
        Valeant Pharmaceuticals
        Takeda
        Sucampo Pharmaceuticals
        McNeil Consumer Healthcare
        Sebela Pharmaceuticals
        Astellas Pharmaceuticals
        IM HealthScience

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        IBS-D Drug
        IBS-C Drug
        Other

        Segment by Application
        Women
        Men

        Buy now